Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study.

Jing LiJian KangChangzheng WangJing YangLinda WangIoannis KottakisMichael HumphriesNanshan Zhongnull null

Published in: Allergy, asthma & immunology research (2016)

Omalizumab improves lung function, quality of life, and asthma control in Chinese patients with moderate-to-severe persistent allergic asthma and has a good safety profile.

Keyphrases

lung function
chronic obstructive pulmonary disease
cystic fibrosis
phase iii
air pollution
allergic rhinitis
clinical trial
high intensity
open label
early onset
phase ii
randomized controlled trial
drug induced